CEL-SCI CORPORATION 10-Q Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 1997, and the nine-month period ended on that date. CEL-SCI Corporation is a biotechnology company focused on the human immunological defense system. The company has limited operating revenues and relies on investment income, equity sales, and borrowings to fund research and development (R&D) and operations. Significant activity during the period included the conversion of preferred stock to common stock and the acquisition of technology rights.
Key Financial Metrics
| Metric | Nine Months Ended June 30, 1997 | Nine Months Ended June 30, 1996 |
|---|---|---|
| Total Income | $378,264 | $188,256 |
| Net Loss | $(6,453,235) | $(4,488,912) |
| Loss Per Share (Diluted) | $(0.72) | $(0.74) |
| Cash and Cash Equivalents (End of Period) | $3,401,150 | $6,646,257 |
| Investments, Net | $1,994,914 | $6,498,812 |
| Total Liabilities | $326,390 | $294,048 |
| Net Cash Used in Operating Activities | $(4,604,446) | $(3,997,580) |
| Net Cash Provided by Investing Activities | $4,160,792 | $(317,242) |
| Net Cash Provided by Financing Activities | $294,994 | $7,074,129 |
Material Changes vs. Prior Period
- Revenue Growth: Total income increased to $378,264 from $188,256, driven primarily by higher interest income ($316,159 vs. $136,651) due to investment holdings.
- Increased Expenses: R&D expenses rose significantly to $4,795,504 from $2,350,600. This increase is attributed to new clinical studies and the expensing of technology acquisitions (Multikine and Cell-Med rights).
- Investment Portfolio: Investments decreased from $6.5 million to $2.0 million as the company sold $5.62 million in investments to fund operations, resulting in a net cash inflow from investing activities of $4.16 million.
- Equity Structure: Significant conversions of Series B and Series C Preferred Stock into common stock occurred during the period. By June 30, 1997, all Series C and remaining Series B preferred shares were converted.
- Cash Position: Cash and cash equivalents declined by approximately $148,660 during the nine-month period, despite investment sales, due to high operating cash burn.
Outlook, Risks, and Management Commentary
- Liquidity Dependence: Management states the company does not anticipate significant revenues until licensing arrangements are secured or products receive approval, which could take years. The company remains dependent on short-term borrowings and securities sales for liquidity.
- Technology Acquisitions: The company purchased rights to Multikine technology (Sittona) and heteroconjugate technology (Cell-Med) in 1997. These were expensed immediately as R&D costs, totaling $1.75 million in stock and $550,000 in cash.
- Warrant Adjustment: Effective June 1, 1997, the exercise price of publicly held warrants was lowered from $15.00 to $6.00, and the conversion ratio was improved (5 warrants per share instead of 10).
- Related Party Transactions: A $300,000 loan to an officer/shareholder was extended, with a balance of $281,900 remaining as of June 30, 1997.
- Risks: The primary risk is the inability to generate revenue before capital is exhausted. The company has a significant accumulated deficit of $36.8 million.
Investor Verification Checklist
- Verify the remaining cash runway given the net operating cash burn of $4.6 million over nine months.
- Confirm the status of clinical trials for cancer and AIDS patients mentioned as drivers of R&D expense.
- Review the terms of the warrant price reduction and its potential dilutive impact on existing shareholders.
- Assess the commercial viability and licensing timeline for the newly acquired Multikine and heteroconjugate technologies.
- Monitor the repayment status of the related-party loan to the officer/shareholder.